Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).
dc.contributor.author | Isaacs, Claudine | |
dc.contributor.author | O'Regan, Ruth | |
dc.contributor.author | Andre, Fabrice | |
dc.contributor.author | Toi, Masakazu | |
dc.contributor.author | Jerusalem, Guy Heinrich Maria | |
dc.contributor.author | Wilks, Sharon | |
dc.contributor.author | Xu, Binghe | |
dc.contributor.author | Masuda, Norikazu | |
dc.contributor.author | Arena, Francis P. | |
dc.contributor.author | Yardley, Denise Aysel | |
dc.contributor.author | Yap, Yoon Sim | |
dc.contributor.author | Mukhopadhyay, Pabak | |
dc.contributor.author | Douma, Shyanne | |
dc.contributor.author | El-Hashimy, Mona | |
dc.contributor.author | Taran, Tanya | |
dc.contributor.author | Sahmoud, Tarek | |
dc.contributor.author | Lebwohl, David Edward | |
dc.contributor.author | Gianni, Luca | |
dc.contributor.author | Ozguroglu, Mustafa | |
dc.date.accessioned | 2021-03-06T10:38:32Z | |
dc.date.available | 2021-03-06T10:38:32Z | |
dc.identifier.citation | O'Regan R., Ozguroglu M., Andre F., Toi M., Jerusalem G. H. M. , Wilks S., Isaacs C., Xu B., Masuda N., Arena F. P. , et al., "Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).", 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31 | |
dc.identifier.other | av_eb53b5e5-bcfc-4399-8bd3-6ece49afd8c8 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/154552 | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Onkoloji | |
dc.title | Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). | |
dc.type | Bildiri | |
dc.contributor.department | , , | |
dc.identifier.volume | 31 | |
dc.contributor.firstauthorID | 141659 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Bildiri [64839]